Travelling to New Zealand with medicinal cannabis

Bringing medicinal cannabis into New Zealand is legal under strict conditions, but it is not a simple “carry your prescription” process. The rules changed when the Misuse of Drugs (Medicinal Cannabis) Amendment Act came into force in April 2020, creating the Medicinal Cannabis Scheme under the Ministry of Health. If you are travelling to New Zealand with medicinal cannabis, you need to follow the customs and health requirements exactly, or your medicine can be confiscated and you may face legal action.

The legal framework: what actually counts as “legal”

Under the Misuse of Drugs Act 1975, cannabis remains a controlled drug in New Zealand. The Medicinal Cannabis Scheme, administered by the Ministry of Health’s Medicinal Cannabis Agency (MCA), does not legalise cannabis generally. It creates a narrow, regulated pathway: a medical practitioner can prescribe a manufactured medicinal cannabis product that meets Good Manufacturing Practice (GMP) standards and has been approved by Medsafe. This is the only lawful route for patients.

The scheme began operating in April 2020, when the Misuse of Drugs (Medicinal Cannabis) Regulations 2019 came into effect. Under those regulations, a prescription from a New Zealand-registered medical practitioner is required. The product must be a “controlled drug” under the Misuse of Drugs Act 1975, and the prescription must be written for a specific patient. There is no general licence to possess or use cannabis for medicinal purposes.

The key distinction: “legal medicinal cannabis” in New Zealand means a manufactured pharmaceutical product that meets GMP standards and is approved by the Ministry of Health. It does not mean a patient can legally smoke raw plant material bought from an unregulated source. Even the raw flower that is available through the scheme is a prescribed, pharmacy-dispensed pharmaceutical product, not a dispensary product. The legal route is always through a medical practitioner, and the product must be sourced through a licensed pharmacy or importer.

What counts as “medicinal cannabis” at the border

For the purposes of bringing medicinal cannabis into New Zealand, the legal definition comes from the Misuse of Drugs Act 1975 and the Misuse of Drugs (Medicinal Cannabis) Regulations 2019. Under that framework, a product is “medicinal cannabis” only if it is a pharmaceutical-grade preparation that meets GMP standards and has been approved by the Ministry of Health under the Medicinal Cannabis Scheme. This is not the same as carrying raw plant material you bought overseas.

New Zealand’s Medicinal Cannabis Scheme (MCS) was established by the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018, which came into force in full on 1 April 2020. Under the scheme, the Medicinal Cannabis Agency (MCA), part of Medsafe, licences the manufacture, supply and possession of medicinal cannabis products. Products must meet GMP (Good Manufacturing Practice) standards and be approved by the Ministry of Health. The NZ Formulary lists products that meet the requirements.

The key legal distinction: carrying medicinal cannabis into New Zealand is only legal if the product meets the requirements of the Medicinal Cannabis Scheme and you have a valid prescription from a New Zealand-registered medical practitioner. A foreign prescription is not automatically valid. You cannot bring raw, unregulated plant material; even if it was prescribed overseas, it must meet NZ’s GMP and product standards.

CBD and THC: what the law actually says

Under the Misuse of Drugs Act 1975, THC is a controlled drug in New Zealand. CBD was reclassified in 2020 and is no longer controlled, but it is still a prescription medicine. The practical difference:

• CBD-only products (no more than 2% THC, or trace amounts below 0.3% in some products) are not controlled drugs, but they still require a prescription from a medical practitioner. A pharmacist can dispense them without a controlled drug licence, but the prescription must be valid.
• THC-containing products are controlled drugs. They require a prescription from a medical practitioner and must be dispensed by a pharmacy. You cannot legally possess them without a prescription, and you cannot import them for personal use without going through the formal pathway.

The Ministry of Health (Medsafe) administers the Medicinal Cannabis Scheme under the Misuse of Drugs Act 1975. The scheme is set out in the Misuse of Drugs (Medicinal Cannabis) Regulations 2019, which came into force on 1 April 2020. Under the regulations, a medical practitioner can prescribe a CBD or THC product that meets GMP standards and is approved by the Ministry of Health. The Medicinal Cannabis Agency (MCA), part of Medsafe, manages licensing and product approvals.

Products available in New Zealand are manufactured to GMP (Good Manufacturing Practice) standards. The two main categories are: - Oils: sublingual drops or oral solutions (onset 30-90 minutes, duration 6-8 hours) - Flower: dried plant material for vaporisation, not smoking (onset 5-10 minutes, duration 2-4 hours)

CBD and THC are the two main cannabinoids. CBD (cannabidiol) is non-psychoactive and often used for anxiety, inflammation, and seizure disorders. THC (delta-9-tetrahydrocannabinol) is psychoactive and often used for pain, appetite, and sleep. Products are labelled with their CBD and THC content in mg/g or as a percentage, and the ratio between the two determines the therapeutic profile.

The legal route is a prescription from a registered medical practitioner. Under the Misuse of Drugs Act 1975, medicinal cannabis products must be approved by the Minister of Health or meet GMP standards. The Medicinal Cannabis Scheme (MCS), established under the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018, sets the rules. The scheme is administered by the Medicinal Cannabis Agency (MCA), which is part of Medsafe. Products must meet GMP standards and be approved by the Ministry of Health. The scheme legalises access via prescription, not a general licence. In practice, most patients get a prescription from their GP, and the product is dispensed by a New Zealand pharmacy.

Products are classified by THC and CBD content. THC is the psychoactive compound; CBD is non-psychoactive. Products range from high-THC flower (e.g., Tilray 25:25, ~25% THC) to high-CBD oils (e.g., CBD100) and balanced ratios (e.g., 10:10). The choice depends on the condition, the desired effect, and the patient’s tolerance. Flower is inhaled and acts in 5-10 minutes, lasting 2-4 hours; oils are taken orally, onset 30-90 minutes, duration 6-8 hours. There is no universal “best” product; the right choice is based on the condition, the patient’s response, and the clinician’s judgment.

The Medicinal Cannabis Scheme under the Misuse of Drugs Act 1975 requires a prescription from a medical practitioner, but not all doctors are willing to prescribe. GPs can prescribe after assessing eligibility, but many defer to specialists. The prescription is written on a standard controlled drug prescription form and must include the product name, strength, and dose. The product must be dispensed by a licensed pharmacist, not sold over the counter. There is no “walk-in” access; a patient cannot buy medicinal cannabis without a prescription.

Products must be GMP-certified and approved by the Ministry of Health. The first product approvals were granted in 2020 under the Medicinal Cannabis Scheme. Products are divided into two categories: those containing >2% CBD (considered a prescription medicine) and those containing ≤2% CBD (considered a controlled drug, but still prescribable). This distinction matters for scheduling, import/export, and pharmacy stocking rules.

The evidence base for medicinal cannabis is mixed and condition-specific. High-quality evidence supports its use for chronic pain (moderate benefit), nausea and vomiting from chemotherapy (established), and spasticity in multiple sclerosis (established). For anxiety, PTSD, and depression, evidence is limited or mixed. For cancer as a disease-modifying treatment, there is no credible evidence; it is used only for symptom management. The NZ Formulary lists cannabis products under “cannabis for medicinal use” and notes that evidence is strongest for chronic pain and chemotherapy-induced nausea; the formulary explicitly says cannabis is not a first-line treatment and should be considered only after standard therapies have failed. Systematic reviews (e.g., Whiting et al., 2015; Stockings et al., 2018; Black et al., 2019) show moderate-quality evidence for chronic pain and spasticity, but weak evidence for most other indications. The NZ Medicinal Cannabis Scheme was enacted in 2018 (Misuse of Drugs (Medicinal Cannabis) Amendment Act), with the first products available in 2020. Medsafe is the regulator under the Ministry of Health, and the Medicinal Cannabis Agency (MCA) manages the scheme. Under the scheme, products must meet GMP standards and be approved by the Ministry of Health; the raw flower, while available, is prescribed and dispensed through a pharmacy. The New Zealand Misuse of Drugs (Medicinal Cannabis) Regulations 2019 set the legal framework. The Ministry of Health publishes the Medicinal Cannabis Guidance. The NZ Formulary lists cannabis products with prescribing notes. Healthify provides patient-facing summaries. The evidence base: a 2023 systematic review in the BMJ found moderate-quality evidence for chronic pain and spasticity; a 2024 meta-analysis in JAMA Network Open found significant reductions in chronic pain, but the authors noted small sample sizes; the International Association for Cannabinoid Medicines (IACM) publishes clinical guidance on dosing; the New Zealand Ministry of Health’s position is that evidence is still evolving and prescribers should follow the NZ Formulary.